Search
Alginic acid
go.drugbank.com/drugs/DB13518ApprovedInvestigationalWithdrawnAlginic acid is a linear polymer consisted of L-glucuronic acid and D-mannuronic acid residues connected via 1,4-glycosidic linkages [A32961]. … It is also available in oral dietary supplements and is found in antacids such as Gaviscon to inhibit gastroesophageal reflux by creating a physical barrier in presence of gastric acid [F46].
Categories: Compounds used in a research, industrial, or household settingSynonyms: (Alginate)n, (Alginate)n+1Phosphatidylinositol Phosphate Metabolism
smpdb.ca/view/SMP0000463MetabolicWhile the phosphoinositides are always located in the membrane, their particular kinases and phosphatases may be found in the cytoplasm or in the membrane of the cell or cell organelles. … Seven different phosphoinositides have been identified in mammals, each distinguished by the number and/or position of the phosphate groups on the inositol ring.
Enzymes: Activating molecule in BECN1-regulated autophagy protein 1Durvalumab
go.drugbank.com/drugs/DB11714ApprovedInvestigational[A192789,L12627] On March 27, 2020, durvalumab was approved by the FDA for use in combination with [etoposide] and either [carboplatin] or [cisplatin] as first-line treatment of patients with extensive-stage … [L12621] In September 2018, durvalumab was approved by the EMA for the treatment of adult patients with locally advanced, unresectable non-small cell lung cancer (NSCLC), only if PD-L1 is expressed in
Carbidopa
go.drugbank.com/drugs/DB00190ApprovedInvestigationaltherapy developed by Mayne Pharma in 1992. … An individual formulation containing solely carbidopa was generated to treat nausea in patients where the combination therapy [levodopa]/carbidopa is not efficient reducing nausea.
Mixtures: LEV/CAR/EN AL100/25/200, LEV/CAR/EN AL200/50/200Telmisartan
go.drugbank.com/drugs/DB00966ApprovedInvestigationalTelmisartan is an angiotensin II receptor antagonist (ARB) used in the management of hypertension. … smooth muscle, ultimately leading to a reduction in arterial blood pressure.
Categories: Angiotensin II receptor antagonists, Angiotensin II Type 1 Receptor BlockersQuetiapine
go.drugbank.com/drugs/DB01224ApprovedInvestigationalInitially approved by the FDA in 1997, quetiapine is a second-generation atypical antipsychotic used in schizophrenia, major depression, and bipolar disorder. … It is well-tolerated and a suitable option for some patients with high sensitivity to other drugs, such as [clozapine] and [olanzapine].[A2189]
Products: FRENI-S IR, Q-PINTislelizumab
go.drugbank.com/drugs/DB14922ApprovedInvestigational[L49439] Tislelizumab was also approved by the FDA on March 14, 2024.[L50346] It has subsequently been approved for additional cancers in the US and EU. [L49349] … This approval was based on positive results demonstrated in the RATIONALE 302 study, where an 8.6-month median overall survival rate was observed for tislelizumab treatment compared to 6.3-month for chemotherapy
Iomeprol
go.drugbank.com/drugs/DB11705ApprovedInvestigational[A265090,A265095] Iomeprol first appeared in the market in 1994 [A265095] and is currently used in various diagnostic processes involving x-ray imaging and computed tomography (CT) scans.[L52260] … Iomeprol is a tri-iodinated, non-ionic radiographic contrast agent for intraarterial or intravenous use.
Categories: Compounds used in a research, industrial, or household settingSynonyms: N,N'-BIS(2,3-DIHYDROXYPROPYL)-2,4,6-TRIIODO-5-(N-METHYLGLYCOLAMIDO)ISOPHTHALAMIDE, 1,3-BENZENEDICARBOXAMIDE, N,N'-BIS(2,3-DIHYDROXYPROPYL)-5-((HYDROXYACETYL)METHYLAMINO)-2,4,6-TRIIODO-Ferumoxytol
go.drugbank.com/drugs/DB06215ApprovedInvestigationalFerumoxytol is an intravenously administered iron preparation previously indicated in the EU and the US for the treatment of iron deficiency anemia in adult patients with chronic kidney disease (CKD) [ … [L54501] The drug remains approved in the US, with a new indication being approved in October of 2025 for Ferumoxytol's use as a diagnostic agent for MRI of the brain.
Categories: Compounds used in a research, industrial, or household settingRelacorilant
go.drugbank.com/drugs/DB14976ApprovedInvestigationalRelacorilant is a first-in-class, selective glucocorticoid receptor antagonist. … [L56089] Relacorilant was approved by the US FDA on March 25, 2026, for use in combination with [paclitaxel] in patients with certain platinum-resistant cancers.[L56093,L56089]